ArticleAmerican journal of cancer research2023
A nomogram based on the log odds of positive lymph nodes for predicting the prognosis of T1 stage rectal cancer.
Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Evaluating log odds of positive lymph nodes as a prognostic tool in differentiated gastric cancer: A retrospective study.World journal of gastroenterology · 2025Article
- Advantage of Log Odds of Metastatic Lymph Nodes After Curative-Intent Resection of Gallbladder Cancer.Annals of surgical oncology · 2025Article
- Development and validation of a nomogram prediction model for overall survival in patients with rectal cancer.World journal of gastrointestinal oncology · 2025Article
- A Prognostic Model Based on the Log Odds Ratio of Positive Lymph Nodes Predicts Prognosis of Patients with Rectal Cancer.Journal of gastrointestinal cancer · 2024Article
- A novel log odds of positive lymph nodes-based nomogram for predicting overall survival in patients with colorectal signet ring cell carcinoma: a SEER population-based study.International journal of colorectal disease · 2024Article
- A novel web-based prognostic nomogram and the features influencing the curative effect of chemotherapy and radiotherapy for Paget's disease with invasive ductal carcinoma.American journal of cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection and timely treatment is the key to improving the prognosis of rectal cancer. Lymph node metastasis is one of the reasons for the poor prognosis of rectal cancer, especially early-stage rectal cancer. In this study, we developed a nomogram based on log odds of positive lymph nodes (LODDS) to predict cancer-specific survival (CSS) in patients with T1 rectal cancer. We included 1934 patients from the Surveillance, Epidemiology, and End Results (SEER) database and divided them into a training cohort and an in-validation cohort. 140 patients from our hospital formed the ex-validation cohort. Multivariate Cox regression analysis indicated that age, sex, grade, and M stage were independent prognostic factors for CSS. LODDS showed better predictive ability than the N stage and PLNs (positive lymph nodes) and was further selected as an independent prognostic factor for the construction of the nomogram. The C-index of the nomogram was 0.743, 0.756, and 0.876 in the training, in-validation, and ex-validation cohorts, respectively. The AUC values of the three cohorts were 0.750, 0.703, and 0.958 at 3 years and 0.731, 0.678, and 0.783 at 5 years. The calibration curves and DCA demonstrated the nomogram's excellent performance. In conclusion, we developed and validated a new nomogram based on LODDS that can effectively predict CSS at 3 and 5 years for patients with T1 rectal cancer.
Indexed as
Identifiers
37168349PMC10164795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.